



## Appendix 40 - SMALL CELL LUNG CANCER (SCLC)

Approved settings/ treatment line	Protocols	Drugs in abbreviation	Evidence level
Limited Stage	Cisplatin + Etoposide (4-6 cycles)		Category 1
	Fractionated cisplatin + Etoposide (4-6 cycles)		Category 2A
	Carboplatin + Etoposide (4-6 cycles)		Category 2A
Extensive Stage	Carboplatin + Etoposide + Atezolizumab maintenance*		Category 1
	Cisplatin + Etoposide		Category 2A
	Carboplatin + Etoposide		Category 2A
	Carboplatin + Irinotecan		Category 2A
	Cisplatin + Irinotecan		Category 2A
Refractory (< 6 months of recurrence)	Topotecan		Category 2A, Preferred
	Ninolumab ± Ipilimumab		Category 2A
	CAV Regimen	cyclophosphamide, doxorubicin, vincristine	Category 2A
	Pembrolizumab		Category 2A
	Docetaxel		Category 2A
	Paclitaxel		Category 2A
	Irinotecan		Category 2A
	Vinorelbine		Category 2A
	Gemcitabine		Category 2A